University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Michael J. Campbell, PhD

Michael J. Campbell, PhD

Assistant Adjunct Professor, Department of Surgery, UCSF

Cancer Center Program Memberships

Breast Oncology

Education

University of Puget Sound, Tacoma, WA, B.S., 1978-1982, Biology
Stanford University, Stanford, CA, Ph.D., 1982-1987, Cancer Biology
Stanford University, Stanford, CA, post-doc, 1987-1989, Tumor immunology and immunotherapy


Professional Experience

  • 1989-1991
    Research Associate, Department of Medicine/Division of Oncology, Stanford University, School of Medicine, Stanford, CA.
  • 1991-1992
    Research Associate, Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • 1992-1997
    Research Assistant Professor, Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • 1997-present
    Assistant Adjunct Professor, Department of Surgery, University of California, San Francisco, CA

Honors & Awards

  • 1982-1986
    NIH - National Research Service Award, Graduate Fellowship
  • 1987-1988
    Stanford University Dean's Postdoctoral Fellowship Award
  • 1988-1989
    NIH - National Research Service Award, Postdoctoral Fellowship

Selected Publications

  1. Campbell MJ, Obasi M, Wu B, Corwin MT, Fananapazir G. The radiographically diagnosed adrenal myelolipoma: what do we really know? Endocrine. 2017 Sep 02.
    View on PubMed
  2. Singh R, Avila J, Jo K, Nguyen KTK, Carrillo NR, Huang EC, Campbell MJ. Patients with Non-invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features are Unlikely to have Malignant Preoperative Cytology. Ann Surg Oncol. 2017 Aug 11.
    View on PubMed
  3. Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper S, Oakes SA, Parsa AT, Lanier LL. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014 Sep 02; 111(35):12823-8.
    View on PubMed
  4. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114.
    View on PubMed
  5. Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ. Biology of breast cancer in Nigerian women: a pilot study. Ann Afr Med. 2012 Jul-Sep; 11(3):169-75.
    View on PubMed
  6. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012 Nov; 19(12):3979-86.
    View on PubMed
  7. Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44.
    View on PubMed
  8. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100.
    View on PubMed
  9. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44.
    View on PubMed
  10. Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, Jones J, Shiry L, Allan G, Maddux BA, Goldfine ID. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. Prostate. 2008 Aug 01; 68(11):1232-40.
    View on PubMed
  11. Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem. 2008 Feb 01; 103(2):624-35.
    View on PubMed
  12. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Res. 2006 Sep 01; 66(17):8707-14.
    View on PubMed
  13. Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice. Cancer Gene Ther. 2006 Nov; 13(11):1002-10.
    View on PubMed
  14. Kumar AS, Campbell M, Benz CC, Esserman LJ. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006 May 01; 24(13):2127; author reply 2127-8.
    View on PubMed
  15. Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther. 2006 Apr; 5(4):1079-86.
    View on PubMed
  16. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat. 2005 Nov; 94(1):37-46.
    View on PubMed
  17. Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res. 2005 Jul; 19(7):649-51.
    View on PubMed
  18. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 2005 May; 91(2):163-71.
    View on PubMed
  19. Kim SW, Chao TH, Xiang R, Lo JF, Campbell MJ, Fearns C, Lee JD. Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells. Cancer Res. 2004 Nov 01; 64(21):7732-9.
    View on PubMed
  20. Shoemaker M, Cohen I, Campbell M. Reduction of MTT by aqueous herbal extracts in the absence of cells. J Ethnopharmacol. 2004 Aug; 93(2-3):381-4.
    View on PubMed

Go to UCSF Profiles, powered by CTSI